troglitazone has been researched along with Colonic Neoplasms in 26 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0." | 3.73 | Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. ( Kohno, H; Sugie, S; Suzuki, R; Tanaka, T, 2005) |
| "Treatment of troglitazone and PDT induced the growth retardation and cell death of DLD-1 cells in a dose-dependent manner, respectively." | 1.43 | Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy. ( Choi, YH; Ko, SH; Lee, JM; Park, H; Park, JH, 2016) |
| "However, some colon cancer cells are resistant to TRAIL because of the expression of anti-apoptotic proteins, such as FLIP." | 1.34 | [The anti-diabetic drug troglitazone sensitizes colon cancer cells to TRAIL-induced apoptosis by down-regulating FLIP]. ( Grund, K; Roth, W; Schirmacher, P; Wiestler, OD, 2007) |
| "PPARgamma is expressed in colon cancer cells." | 1.33 | [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth]. ( Chen, HN; Cui, W; Koirala, K; Liu, YC; Wan, YL; Wang, CL; Wang, HY; Wang, X; Zhu, J, 2006) |
| "Troglitazone is an inductor of PPARgamma in colon cancer cells and inhibits PPARgamma-dependently proliferation, which may attribute to cell cycle G1 arrest and apoptosis in colon cancer cells." | 1.33 | Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells. ( Luo, HS; Meng, XZ; Ming, M; Yu, HG; Yu, JP; Zhou, YH, 2006) |
| "Treatment with troglitazone increased apoptosis and decreased polyamine content and ornithine decarboxylase (ODC) activity in the colonic mucosa of rats treated with AOM." | 1.31 | Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. ( Hosokawa, M; Kohno, H; Okumura, A; Takashima, S; Tanaka, T; Yamaguchi, N; Yoshitani , S, 2001) |
| "Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer." | 1.30 | Differentiation and reversal of malignant changes in colon cancer through PPARgamma. ( Chen, LB; DeAngelo, DJ; Fletcher, C; Holden, SA; Jones, D; King, FJ; Mueller, E; Partridge, JB; Sarraf, P; Singer, S; Spiegelman, BM, 1998) |
| "In conclusion, human colon cancer cells express PPAR gamma, the ligands of which inhibit cell growth and induce differentiation markers." | 1.30 | Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. ( Kanayama, S; Kitamura, S; Kondo, S; Matsuzawa, Y; Miyazaki, Y; Shinomura, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 20 (76.92) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vesci, L | 1 |
| Milazzo, FM | 1 |
| Stasi, MA | 1 |
| Pace, S | 1 |
| Manera, F | 1 |
| Tallarico, C | 1 |
| Cini, E | 1 |
| Petricci, E | 1 |
| Manetti, F | 1 |
| De Santis, R | 1 |
| Giannini, G | 1 |
| Koyama, M | 1 |
| Sowa, Y | 1 |
| Horinaka, M | 1 |
| Goda, AE | 1 |
| Fujiwara, J | 1 |
| Sakai, T | 1 |
| Park, H | 1 |
| Ko, SH | 1 |
| Lee, JM | 1 |
| Park, JH | 1 |
| Choi, YH | 1 |
| Qiao, L | 3 |
| Dai, Y | 3 |
| Gu, Q | 3 |
| Chan, KW | 2 |
| Zou, B | 3 |
| Ma, J | 3 |
| Wang, J | 2 |
| Lan, HY | 3 |
| Wong, BC | 3 |
| Li, GH | 1 |
| Li, Z | 1 |
| Pang, R | 1 |
| Ban, JO | 1 |
| Kwak, DH | 1 |
| Oh, JH | 1 |
| Park, EJ | 1 |
| Cho, MC | 1 |
| Song, HS | 1 |
| Song, MJ | 1 |
| Han, SB | 1 |
| Moon, DC | 1 |
| Kang, KW | 1 |
| Hong, JT | 1 |
| Osawa, E | 1 |
| Nakajima, A | 1 |
| Wada, K | 1 |
| Ishimine, S | 1 |
| Fujisawa, N | 1 |
| Kawamori, T | 1 |
| Matsuhashi, N | 1 |
| Kadowaki, T | 1 |
| Ochiai, M | 1 |
| Sekihara, H | 1 |
| Nakagama, H | 1 |
| Burgermeister, E | 1 |
| Tencer, L | 1 |
| Liscovitch, M | 1 |
| Kato, M | 1 |
| Kusumi, T | 1 |
| Tsuchida, S | 1 |
| Tanaka, M | 1 |
| Sasaki, M | 1 |
| Kudo, H | 1 |
| Hosokawa, M | 4 |
| Kudo, M | 1 |
| Maeda, H | 1 |
| Kohno, H | 5 |
| Tanaka, T | 5 |
| Miyashita, K | 2 |
| Yang, K | 1 |
| Fan, KH | 1 |
| Lamprecht, SA | 1 |
| Edelmann, W | 1 |
| Kopelovich, L | 1 |
| Kucherlapati, R | 1 |
| Lipkin, M | 1 |
| Suzuki, R | 1 |
| Sugie, S | 1 |
| Bouancheau, D | 1 |
| Buecher, B | 1 |
| Jarry, A | 1 |
| Simon, B | 1 |
| Masson, D | 1 |
| Cassagnau, E | 1 |
| Hamelin, R | 1 |
| Laboisse, CL | 1 |
| Bézieau, S | 1 |
| Denis, MG | 1 |
| Koirala, K | 1 |
| Wan, YL | 1 |
| Liu, YC | 1 |
| Wang, X | 1 |
| Cui, W | 1 |
| Wang, CL | 1 |
| Chen, HN | 1 |
| Wang, HY | 1 |
| Zhu, J | 1 |
| Yasui, Y | 1 |
| Fiatte, C | 1 |
| Huin, C | 1 |
| Bertin, I | 1 |
| Lesuffleur, T | 1 |
| Pluvinet, A | 1 |
| Touche, N | 1 |
| Plénat, F | 1 |
| Dauça, M | 1 |
| Domenjoud, L | 1 |
| Schohn, H | 1 |
| Ming, M | 1 |
| Yu, JP | 1 |
| Meng, XZ | 1 |
| Zhou, YH | 1 |
| Yu, HG | 1 |
| Luo, HS | 1 |
| Roth, W | 1 |
| Grund, K | 1 |
| Wiestler, OD | 1 |
| Schirmacher, P | 1 |
| Komatsu, Y | 1 |
| Ito, I | 1 |
| Wayama, M | 1 |
| Fujimura, A | 1 |
| Akaogi, K | 1 |
| Machida, H | 1 |
| Nakajima, Y | 1 |
| Kuroda, T | 1 |
| Ohmori, K | 1 |
| Murayama, A | 1 |
| Kimura, K | 1 |
| Yanagisawa, J | 1 |
| Rocken, C | 1 |
| Ebert, MP | 1 |
| Sarraf, P | 1 |
| Mueller, E | 1 |
| Jones, D | 1 |
| King, FJ | 1 |
| DeAngelo, DJ | 1 |
| Partridge, JB | 1 |
| Holden, SA | 1 |
| Chen, LB | 1 |
| Singer, S | 1 |
| Fletcher, C | 1 |
| Spiegelman, BM | 1 |
| Kitamura, S | 1 |
| Miyazaki, Y | 1 |
| Shinomura, Y | 1 |
| Kondo, S | 1 |
| Kanayama, S | 1 |
| Matsuzawa, Y | 1 |
| Yoshitani, S | 1 |
| Takashima, S | 2 |
| Okumura, A | 2 |
| Murakami, A | 1 |
| Yoshitani , S | 1 |
| Yamaguchi, N | 1 |
| Shimada, T | 1 |
| Kojima, K | 1 |
| Yoshiura, K | 1 |
| Hiraishi, H | 1 |
| Terano, A | 1 |
| Sunami, E | 1 |
| Tsuno, NH | 1 |
| Kitayama, J | 1 |
| Saito, S | 1 |
| Osada, T | 1 |
| Yamaguchi, H | 1 |
| Tomozawa, S | 1 |
| Tsuruo, T | 1 |
| Shibata, Y | 1 |
| Nagawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer[NCT00923949] | Phase 2 | 1 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Study never published; terminated early due to low accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the number of participants with adverse events. For details about the adverse events see the adverse event module. (NCT00923949)
Timeframe: 58 days
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone | 1 |
26 other studies available for troglitazone and Colonic Neoplasms
| Article | Year |
|---|---|
Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dos | 2018 |
Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Binding Sites; Cell Line, Tumor; Ch | 2014 |
Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell P | 2016 |
Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition in colon cancer.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Colonic Neoplasm | 2008 |
Gene expression profile in colon cancer cells with respect to XIAP expression status.
Topics: Apoptosis; Blotting, Western; Cell Proliferation; Chromans; Colonic Neoplasms; Gene Expression Profi | 2009 |
Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
Topics: Cell Cycle; Cell Division; Chromans; Colonic Neoplasms; Electrophoretic Mobility Shift Assay; Flow C | 2010 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Femal | 2003 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveoli | 2003 |
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Cell Differentiation; Cell Line, | 2004 |
Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Pro | 2004 |
Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinogens; Carrier Proteins; | 2005 |
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bezafibrate; Body Weight; Chromans; Col | 2005 |
The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromans; Colonic Neoplasms; DNA Mutational A | 2005 |
[Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferatio | 2006 |
Troglitazone and 9cis,11trans,13trans-conjugated linolenic acid: comparison of their antiproliferative and apoptosis-inducing effects on different colon cancer cell lines.
Topics: alpha-Linolenic Acid; Antineoplastic Agents; Apoptosis; Blotting, Western; Caco-2 Cells; Cell Differ | 2006 |
Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Topics: Base Sequence; Caco-2 Cells; Chromans; Chromosome Mapping; Colonic Neoplasms; Cycloheximide; Dactino | 2006 |
Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Chromans; Colonic Neo | 2006 |
[The anti-diabetic drug troglitazone sensitizes colon cancer cells to TRAIL-induced apoptosis by down-regulating FLIP].
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Chromans; | 2007 |
PPARgamma ligands suppress the feedback loop between E2F2 and cyclin-E1.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Chromans; Colonic Neoplasms; Cyclin E; E2F2 Tra | 2008 |
Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Chromans; Colonic | 2008 |
Differentiation and reversal of malignant changes in colon cancer through PPARgamma.
Topics: Adenocarcinoma; Animals; Cell Differentiation; Cell Division; Chromans; Colonic Neoplasms; Gene Expr | 1998 |
Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.
Topics: Calcium-Binding Proteins; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Colonic N | 1999 |
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Bezafibrate; Cell Division; Chromans; Colitis; Colon | 2001 |
Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azoxymethane; Biogenic Polyamines; Carcinogens; Chromans; | 2001 |
Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells.
Topics: Apoptosis; Cell Division; Cell Survival; Chromans; Colonic Neoplasms; DNA, Complementary; DNA, Neopl | 2002 |
Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Adhesion; Cell Division; Chromans; Collage | 2002 |